CTRI/2020/03/023968招募中未知
Clinical Trial of Gliclazide Extended Release 60 mg (DIAMICRON XR 60) in Indian MODY patients with MODY 1,3 &12
DrVMohan0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Adult Patients aged 7-30 (ends inclusive) of either gender diagnosed who are diagnosed with MODY 1, MODY 3 or MODY 12
- •2.Body Mass Index ( < 30 kg/m2)
- •3.Family history of diabetes in one or both of the parents
- •4.Duration of diabetes less than 2 years
- •5.Patients who understands the nature of study and willing to provide a written informed consent
排除标准
- •Patient will excluded if they have any of the following:
- •1.Type 1 diabetes
- •2.Type 2 diabetes
- •3.Gestational diabetes
- •4.Fibrocalculous pancreatic diabetes
- •5.Presence of acanthosis nigricans or severe obesity
- •6.History of serious infection / surgical procedure / Severe trauma in past 4 weeks or planned surgery during the study period of 12 weeks
- •7.History or evidence of significant cardiovascular disorder including but not limited to, heart failure, myocardial infarction or any conduction abnormality on ECG viz QT prolongation, Arrhythmias
- •8.History or risk of Acute Pancreatitis
- •9.History of Chronic Alcoholism or drug abuse
- •10.Pregnant or breast-feeding women
- •11.A subject who is judged by the investigator as inappropriate to participate in the study for any reason other than those mentioned above.
研究者
相似试验
尚未招募
不适用
Bioequivalence study of Gliclazide 60 mg Extended Release Tablet (Tehran Chemie) versus Diamicron MR (SERVIER) Tablet after single oral dosing in healthy volunteersIRCT20220111053692N7Tehran Chemie Pharmaceutical Company24
已完成
不适用
Bioequivalence study of Gliclazide 60 mg Extended Release Tablet (Darou Darman Ariya Sepahan) versus Diamicron MR (SERVIER) Tablet after single oral dosing in healthy volunteersIRCT20220111053692N6Aria Sepahan Pharmaceutical Co24
招募中
不适用
Bioequivalence study of Gliclazide 60 mg Extended Release Tablet (Tehran Darou) versus Diamicron MR (SERVIER) Tablet after single oral dosing in healthy volunteersIRCT20220111053692N8tehran darou Pharmaceutical Company24
进行中（未招募）
1 期
Efficacy and safety of gliclazide MR (30 to 120 mg per day) associated or not to metformine or to an a-glucosidase inhibitor during the fast of the Ramadan in type 2 diabetic patients.A 5 to 8 months, national, multicentre, open study.Efficacité et tolérance du gliclazide LM (30 à 120 mg/j per os) associé ou non à la metformine ou à un inhibiteur des a-glucosidases pendant le jeûne du Ramadan chez des patients diabétiques de type 2. Etude nationale, multicentrique de 5 à 8 mois de traitement en ouvert.Diabetes mellitus non insulino dependantMedDRA version: 9.1Level: SOCClassification code 10027433Term: Metabolism and nutrition disordersEUCTR2006-006754-10-FRInstitut de Recherches Internationales Servier
已完成
Unknown
Bioequivalence study of Gliclazide 30 mg Extended Release Tablet (Darou Darman Ariya Sepahan) versus Diamicron MR (SERVIER) Tablet after single oral dosing in healthy volunteersBioequivalence study of Gliclazide 30 mg Extended Release Tablet (Darou Darman Ariya Sepahan) versus Diamicron MR (SERVIER) Tablet after single oral dosing in healthy volunteers.IRCT20220111053692N9Aria Sepahan Pharmaceutical Co24